Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indevus Gains Supprelin LA With Purchase Of Valera

This article was originally published in The Pink Sheet Daily

Executive Summary

Indevus also expects to out-license Valera's early stage pipeline, as well as several of its own products.

You may also be interested in...



Indevus’ Valstar Is “Approvable” At FDA

Agency seeks clarification of manufacturing validation protocols described in the firm’s sNDA for the bladder cancer treatment.

Indevus’ Valstar Is “Approvable” At FDA

Agency seeks clarification of manufacturing validation protocols described in the firm’s sNDA for the bladder cancer treatment.

Indevus Gains Sanctura XR Approval

The molecule’s “highly differentiated profile” will set it apart from others in the crowded urinary incontinence space, Indevus tells “The Pink Sheet” DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel